BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
TEL AVIV, Israel, May 01, 2018 -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, May 17 at 8:30am Eastern Time to report first quarter ended March 31, 2018 financial results.
Thursday, May 17th @ 8:30am Eastern Time
US Domestic: 877-222-6394
International: 1-703-925-2702
Conference ID: 9993639
Webcast: https://edge.media-server.com/m6/p/zja7xger
Replays, Available through May 31, 2018
US Domestic: 855-859-2056
International: 1-404-537-3406
Conference ID: 9993639
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 trial for platinum-resistant ovarian cancer.
INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979
